Current trends in the pharmacological management of Chagas disease
| Autor: | Riccardo Pratesi, Nayra Dias, Mariana Hecht, Nadjar Nitz, Vanessa Coelho Ribeiro, Luciana Hagström-Bex, Taís Paiva |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Drug Chagas disease medicine.medical_specialty Drugs repositioning Trypanosoma cruzi media_common.quotation_subject 030231 tropical medicine MEDLINE Disease Drugs association Article lcsh:Infectious and parasitic diseases Mice 03 medical and health sciences 0302 clinical medicine medicine Global health Animals Humans Pharmacology (medical) lcsh:RC109-216 Intensive care medicine Nifurtimox media_common Pharmacology Clinical Trials as Topic business.industry Drug Repositioning Disease Management medicine.disease Trypanocidal Agents New drugs Drug repositioning Treatment Outcome 030104 developmental biology Infectious Diseases Benznidazole Parasitology business Pharmacological treatment medicine.drug |
| Zdroj: | International Journal for Parasitology: Drugs and Drug Resistance, Vol 12, Iss, Pp 7-17 (2020) International Journal for Parasitology: Drugs and Drug Resistance |
| ISSN: | 2211-3207 |
| Popis: | Chagas disease (CD) is a tropical neglected illness, affecting mainly populations of low socioeconomic status in Latin America. An estimated 6 to 8 million people worldwide are infected with Trypanosoma cruzi, the etiological agent of CD. Despite being one of the main global health problems, this disease continues without effective treatment during the chronic phase of the infection. The limitation of therapeutic strategies has been one of the biggest challenges on the fight against CD. Nifurtimox and benznidazole, developed in the 1970s, are still the only commercial options with established efficacy on CD. However, the efficacy of these drugs have a proven efficacy only during early infection and the benefits in the chronic phase are questionable. Consequently, there is a growing need for new pharmacological alternatives, either by optimization of existing drugs or by the formulation of new compounds. In the present study, a literature review of the currently adopted therapy, its concomitant combination with other drugs, and potential future treatments for CD was performed, considering articles published from 2012. The revised articles were selected according to the protocol of treatment: evaluation of drug association, drug repositioning and research of new drugs. As a result of the present revision, it was possible to conclude that the use of benznidazole in combination with other compounds showed better results when compared with its use as a single therapy. The search of new drugs has been the strategy most used in pursuing more effective forms of treatment for CD. However, studies have still focused on basic research, that is, they are still in a pre-clinical stage, using methodologies based on in vitro or in animal studies. Highlights • There is no effective treatment for chronic Chagas disease. • Association of benznidazole with other drugs is more efficient than benznidazole alone. • Nowadays, most researches focus on the development of new drugs to combat Chagas disease. • Current studies are still in a pre-clinical stage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|